» Articles » PMID: 30344006

T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease

Overview
Publisher Cell Press
Specialty Cell Biology
Date 2018 Oct 23
PMID 30344006
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson disease (PD) is a progressive neurological disease caused by selective degeneration of dopaminergic (DA) neurons in the substantia nigra. Although most cases of PD are sporadic cases, familial PD provides a versatile research model for basic mechanistic insights into the pathogenesis of PD. In this study, we generated DA neurons from PARK2 patient-specific, isogenic PARK2 null and PARK6 patient-specific induced pluripotent stem cells and found that these neurons exhibited more apoptosis and greater susceptibility to rotenone-induced mitochondrial stress. From phenotypic screening with an FDA-approved drug library, one voltage-gated calcium channel antagonist, benidipine, was found to suppress rotenone-induced apoptosis. Furthermore, we demonstrated the dysregulation of calcium homeostasis and increased susceptibility to rotenone-induced stress in PD, which is prevented by T-type calcium channel knockdown or antagonists. These findings suggest that calcium homeostasis in DA neurons might be a useful target for developing new drugs for PD patients.

Citing Articles

Computational model of the spatiotemporal synergetic system dynamics of calcium, IP and dopamine in neuron cells.

Pawar A, Pardasani K Cogn Neurodyn. 2024; 18(5):2709-2729.

PMID: 39678722 PMC: 11639382. DOI: 10.1007/s11571-024-10117-w.


Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology.

Currim F, Tanwar R, Brown-Leung J, Paranjape N, Liu J, Sanders L Neurotoxicology. 2024; 103:266-287.

PMID: 38964509 PMC: 11288778. DOI: 10.1016/j.neuro.2024.06.016.


Potential Applications of Mitochondrial Therapy with a Focus on Parkinson's Disease and Mitochondrial Transplantation.

Wal P, Wal A, Vig H, Mahmood D, Khan M Adv Pharm Bull. 2024; 14(1):147-160.

PMID: 38585467 PMC: 10997929. DOI: 10.34172/apb.2024.019.


Stem Cell-Based Approaches in Parkinson's Disease Research.

Kim M, Yoon S, Choi J, Kim Y, Lee G Int J Stem Cells. 2024; 18(1):21-36.

PMID: 38449089 PMC: 11867902. DOI: 10.15283/ijsc23169.


iSCORE-PD: an isogenic stem cell collection to research Parkinson's Disease.

Busquets O, Li H, Syed K, Jerez P, Dunnack J, Lo Bu R bioRxiv. 2024; .

PMID: 38405931 PMC: 10888955. DOI: 10.1101/2024.02.12.579917.


References
1.
Ren Y, Jiang H, Hu Z, Fan K, Wang J, Janoschka S . Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons. Stem Cells. 2014; 33(1):68-78. PMC: 4429885. DOI: 10.1002/stem.1854. View

2.
. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord. 2013; 28(13):1823-31. DOI: 10.1002/mds.25639. View

3.
Suda Y, Kuzumaki N, Sone T, Narita M, Tanaka K, Hamada Y . Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction. Mol Brain. 2018; 11(1):6. PMC: 5819262. DOI: 10.1186/s13041-018-0349-8. View

4.
Gomez-Sanchez R, Gegg M, Bravo-San Pedro J, Niso-Santano M, Alvarez-Erviti L, Pizarro-Estrella E . Mitochondrial impairment increases FL-PINK1 levels by calcium-dependent gene expression. Neurobiol Dis. 2013; 62:426-40. PMC: 3898697. DOI: 10.1016/j.nbd.2013.10.021. View

5.
Curtis T, Scholfield C . Nifedipine blocks Ca2+ store refilling through a pathway not involving L-type Ca2+ channels in rabbit arteriolar smooth muscle. J Physiol. 2001; 532(Pt 3):609-23. PMC: 2278590. DOI: 10.1111/j.1469-7793.2001.0609e.x. View